Companies › Jiangsu vcare pharmaceutical technology
3 active drug programs in 9 registered trials: 5 Phase 3, 3 Phase 2, 1 Phase 1; Immunology, Cardiovascular, Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VC004 | – | Phase 3 | Locally Advanced Solid Tumor | Dec 2026 |
| Vicagrel P2Y12 receptor antagonist | P2RY12 | Phase 3 | Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) | Dec 2026 |
| VC005 tablets JAK inhibitor | – | Phase 3 | Active Ankylosing Spondylitis; Moderate to Severe Atopic Dermatitis; Atopic Dermatitis; Non-segmental Vitiligo … | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06577519 | Vicagrel | Phase 3 | Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) | Cardiovascular | Dec 2026 |
| NCT06658353 | VC004 | Phase 3 | Locally Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT07598383 | VC005 tablets | Phase 2 | Atopic Dermatitis | Immunology | Feb 2027 |
| NCT07172360 | VC005 tablets | Phase 3 | Active Ankylosing Spondylitis | Immunology | Aug 2027 |
| NCT06723080 | VC005 tablets | Phase 3 | Moderate to Severe Atopic Dermatitis | Immunology | Aug 2027 |
| NCT07172347 | VC005 tablets | Phase 2 | Non-segmental Vitiligo | Immunology | Aug 2027 |
| NCT07762443 | VC005 tablets | Phase 1 | Alopecia Areata | Immunology | Dec 2027 |
| NCT07592585 | VC005 tablets | Phase 3 | Atopic Dermatitis | Immunology | May 2028 |
| NCT07749716 | VC005 tablets | Phase 2 | Alopecia Areata | Immunology | Dec 2028 |
iVascular S.L.U. Viatris Innovation Industrial Farmacéutica Cantabria THPharm Swedish Orphan Biovitrum
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.